Nothing Special   »   [go: up one dir, main page]

MX2019006045A - Proteinas triespecificas dirigidas a psma y metodos de uso. - Google Patents

Proteinas triespecificas dirigidas a psma y metodos de uso.

Info

Publication number
MX2019006045A
MX2019006045A MX2019006045A MX2019006045A MX2019006045A MX 2019006045 A MX2019006045 A MX 2019006045A MX 2019006045 A MX2019006045 A MX 2019006045A MX 2019006045 A MX2019006045 A MX 2019006045A MX 2019006045 A MX2019006045 A MX 2019006045A
Authority
MX
Mexico
Prior art keywords
psma
targeting trispecific
trispecific proteins
methods
psma targeting
Prior art date
Application number
MX2019006045A
Other languages
English (en)
Inventor
B Dubridge Robert
Wesche Holger
Baeuerle Patrick
Seto Pui
J Austin Richard
Guenot Jeanmarie
D Lemon Bryan
Original Assignee
Harpoon Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harpoon Therapeutics Inc filed Critical Harpoon Therapeutics Inc
Publication of MX2019006045A publication Critical patent/MX2019006045A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pregnancy & Childbirth (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

En el presente documento se proporcionan proteínas específicas dirigidas al Antígeno Prostático Específico de Membrana (PSMA) que comprenden un dominio unido a CD3, un dominio de extensión de vida media y un dominio unido al PSMA. También se proporcionan composiciones farmacéuticas del mismo, así como ácidos nucleicos, vectores de expresión recombinantes y células huésped, para la obtención de dichas proteínas triespecíficas dirigidas al PSMA. También se describen métodos para emplear proteínas triespecíficas dirigidas al PSMA en la prevención o el tratamiento de enfermedades, afecciones y trastornos.
MX2019006045A 2016-11-23 2017-11-22 Proteinas triespecificas dirigidas a psma y metodos de uso. MX2019006045A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662426069P 2016-11-23 2016-11-23
US201662426077P 2016-11-23 2016-11-23
PCT/US2017/063126 WO2018098356A1 (en) 2016-11-23 2017-11-22 Psma targeting trispecific proteins and methods of use

Publications (1)

Publication Number Publication Date
MX2019006045A true MX2019006045A (es) 2019-11-11

Family

ID=62196141

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019006045A MX2019006045A (es) 2016-11-23 2017-11-22 Proteinas triespecificas dirigidas a psma y metodos de uso.

Country Status (11)

Country Link
US (2) US10844134B2 (es)
EP (1) EP3544629A4 (es)
JP (1) JP7215997B2 (es)
KR (1) KR20190087539A (es)
CN (1) CN110198737A (es)
AU (1) AU2017363302A1 (es)
BR (1) BR112019010602A2 (es)
CA (1) CA3044729A1 (es)
IL (1) IL266801A (es)
MX (1) MX2019006045A (es)
WO (1) WO2018098356A1 (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111234027A (zh) 2015-05-21 2020-06-05 哈普恩治疗公司 三特异性结合蛋白质及使用方法
IL307276A (en) 2015-08-28 2023-11-01 Amunix Operating Inc Chimeric polypeptide composition and methods for its preparation and use
MX2018014227A (es) 2016-05-20 2019-08-22 Harpoon Therapeutics Inc Proteinas de union de cadena unica de fragmento variable cd3.
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
EP3493844A4 (en) 2016-05-20 2021-03-24 Harpoon Therapeutics Inc. SINGLE DOMAIN SERIAL ALBUMIN BINDING PROTEIN
MX2019006045A (es) 2016-11-23 2019-11-11 Harpoon Therapeutics Inc Proteinas triespecificas dirigidas a psma y metodos de uso.
CN110198955A (zh) 2016-11-23 2019-09-03 哈普恩治疗公司 前列腺特异性膜抗原结合蛋白质
US11535668B2 (en) 2017-02-28 2022-12-27 Harpoon Therapeutics, Inc. Inducible monovalent antigen binding protein
US20200270362A1 (en) * 2017-05-12 2020-08-27 Harpoon Therapeutics, Inc. Msln targeting trispecific proteins and methods of use
CN113896792A (zh) 2017-05-12 2022-01-07 哈普恩治疗公司 间皮素结合蛋白质
JP7209936B2 (ja) 2017-05-12 2023-01-23 ハープーン セラピューティクス，インク． Ｍｓｌｎ標的三重特異性タンパク質及びその使用方法
AU2018347582A1 (en) 2017-10-13 2020-05-07 Harpoon Therapeutics, Inc. Trispecific proteins and methods of use
KR20220111743A (ko) 2017-10-13 2022-08-09 하푼 테라퓨틱스, 인크. B 세포 성숙화 항원 결합 단백질
WO2019237081A1 (en) * 2018-06-07 2019-12-12 Cullinan Management, Inc. Multi-specific binding proteins and methods of use thereof
WO2020061482A1 (en) * 2018-09-21 2020-03-26 Harpoon Therapeutics, Inc. Egfr binding proteins and methods of use
US10815311B2 (en) 2018-09-25 2020-10-27 Harpoon Therapeutics, Inc. DLL3 binding proteins and methods of use
CN114245806A (zh) 2019-05-14 2022-03-25 哈普恩治疗公司 EpCAM结合蛋白及使用方法
WO2021163364A1 (en) * 2020-02-12 2021-08-19 Abbvie Biotechnology Ltd. Trispecific binding molecules
CA3170833A1 (en) 2020-02-21 2021-08-26 Harpoon Therapeutics, Inc. Flt3 binding proteins and methods of use
WO2021231434A1 (en) * 2020-05-12 2021-11-18 Harpoon Therapeutics, Inc. Psma targeting tritacs and methods of use
CA3188601A1 (en) * 2020-07-08 2022-01-13 LAVA Therapeutics N.V. Antibodies that bind psma and gamma-delta t cell receptors
US20230398147A1 (en) 2020-09-16 2023-12-14 Amgen Inc. Methods for administering therapeutic doses of bispecific t-cell engaging molecules for the treatment of cancer
EP4259193A1 (en) 2020-12-09 2023-10-18 Janux Therapeutics, Inc. Compositions and methods related to tumor activated antibodies targeting psma and effector cell antigens
EP4284838A2 (en) * 2021-01-28 2023-12-06 Janssen Biotech, Inc. Psma binding proteins and uses thereof
CA3208069A1 (en) * 2021-03-09 2022-09-15 Mary Ellen Molloy Combination therapy with immune cell engaging proteins and immunomodulators
WO2022212732A1 (en) * 2021-04-01 2022-10-06 Harpoon Therapeutics, Inc. Psma targeting tritacs and methods of use
JP2024517701A (ja) 2021-04-29 2024-04-23 アムジエン・インコーポレーテツド 組換え生産タンパク質の低分子量種を低減させる方法
CN118556077A (zh) * 2021-11-17 2024-08-27 南京再明医药有限公司 一种多特异性抗体及其药物用途
AU2023238724A1 (en) 2022-03-21 2024-09-05 Amgen Inc. Combination therapy methods with t-cell engaging molecules for treatment of prostate cancer
WO2023224912A1 (en) * 2022-05-16 2023-11-23 Regeneron Pharmaceuticals, Inc. Methods of treating metastatic castration-resistant prostate cancer with bispecific anti-psma x anti-cd3 antibodies alone or in combination with anti-pd-1 antibodies
WO2024035953A2 (en) * 2022-08-11 2024-02-15 Adicet Therapeutics, Inc. Affinity binding entities directed to psma and methods of use thereof

Family Cites Families (200)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR901228A (fr) 1943-01-16 1945-07-20 Deutsche Edelstahlwerke Ag Système d'aimant à entrefer annulaire
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5061620A (en) 1990-03-30 1991-10-29 Systemix, Inc. Human hematopoietic stem cell
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
US5199942A (en) 1991-06-07 1993-04-06 Immunex Corporation Method for improving autologous transplantation
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
WO1993007105A1 (en) 1991-10-04 1993-04-15 Iit Research Institute Conversion of plastic waste to useful oils
GB9125768D0 (en) 1991-12-04 1992-02-05 Hale Geoffrey Therapeutic method
CA2507749C (en) 1991-12-13 2010-08-24 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
ES2338791T3 (es) 1992-08-21 2010-05-12 Vrije Universiteit Brussel Inmunoglobulinas desprovistas de cadenas ligeras.
US5350674A (en) 1992-09-04 1994-09-27 Becton, Dickinson And Company Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
US5773292A (en) 1995-06-05 1998-06-30 Cornell University Antibodies binding portions, and probes recognizing an antigen of prostate epithelial cells but not antigens circulating in the blood
US6107090A (en) 1996-05-06 2000-08-22 Cornell Research Foundation, Inc. Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains
US6136311A (en) 1996-05-06 2000-10-24 Cornell Research Foundation, Inc. Treatment and diagnosis of cancer
ATE461282T1 (de) 1997-10-27 2010-04-15 Bac Ip Bv Multivalente antigenbindende proteine
AU3596599A (en) 1998-01-26 1999-08-09 Unilever Plc Method for producing antibody fragments
CZ121599A3 (cs) 1998-04-09 1999-10-13 Aventis Pharma Deutschland Gmbh Jednořetězcová molekula vázající několik antigenů, způsob její přípravy a léčivo obsahující tuto molekulu
ATE276359T1 (de) 1999-01-19 2004-10-15 Unilever Nv Verfahren zur herstellung von antikörperfragmenten
US6326193B1 (en) 1999-11-05 2001-12-04 Cambria Biosciences, Llc Insect control agent
US20060228364A1 (en) 1999-12-24 2006-10-12 Genentech, Inc. Serum albumin binding peptides for tumor targeting
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
IL151287A0 (en) 2000-02-24 2003-04-10 Xcyte Therapies Inc A method for stimulation and concentrating cells
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
AU2001268855A1 (en) 2000-05-26 2001-12-03 National Research Council Of Canada Single-domain antigen-binding antibody fragments derived from llama antibodies
WO2001096584A2 (en) 2000-06-12 2001-12-20 Akkadix Corporation Materials and methods for the control of nematodes
CN1294148C (zh) 2001-04-11 2007-01-10 中国科学院遗传与发育生物学研究所 环状单链三特异抗体
GB0110029D0 (en) 2001-04-24 2001-06-13 Grosveld Frank Transgenic animal
CN1195779C (zh) 2001-05-24 2005-04-06 中国科学院遗传与发育生物学研究所 抗人卵巢癌抗人cd3双特异性抗体
US7666414B2 (en) 2001-06-01 2010-02-23 Cornell Research Foundation, Inc. Methods for treating prostate cancer using modified antibodies to prostate-specific membrane antigen
EP1433793A4 (en) 2001-09-13 2006-01-25 Inst Antibodies Co Ltd METHOD FOR CREATING A CAMEL ANTIBODY LIBRARY
US20050215472A1 (en) 2001-10-23 2005-09-29 Psma Development Company, Llc PSMA formulations and uses thereof
WO2003034903A2 (en) 2001-10-23 2003-05-01 Psma Development Company, L.L.C. Psma antibodies and protein multimers
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
EP1519747A4 (en) 2002-01-28 2006-03-29 Medarex Inc HUMAN MONOCLONAL ANTIBODIES AGAINST PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA)
DK1517921T3 (da) 2002-06-28 2006-10-09 Domantis Ltd Immunglobulin-enkeltvariable antigen-bindende domæner og dobbeltspecifikke konstruktioner deraf
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
NZ540219A (en) 2002-11-07 2008-08-29 Univ Erasmus Fret probes and methods for detecting interacting molecules
EP2284192A3 (en) 2002-11-08 2011-07-20 Ablynx N.V. Camelidae antibodies for sublingual administration
ES2551682T3 (es) 2002-11-08 2015-11-23 Ablynx N.V. Anticuerpos de dominio simple dirigidos contra factor de necrosis tumoral-alfa y usos para los mismos
US9320792B2 (en) 2002-11-08 2016-04-26 Ablynx N.V. Pulmonary administration of immunoglobulin single variable domains and constructs thereof
BRPI0316092B8 (pt) 2002-11-08 2021-05-25 Ablynx Nv anticorpos de domínio único direcionados contra o fator de necrose tumoral alfa e usos para os mesmos
GB0228210D0 (en) 2002-12-03 2003-01-08 Babraham Inst Single chain antibodies
US8784821B1 (en) 2003-05-31 2014-07-22 Amgen Research (Munich) Gmbh Human-anti-human cd3 binding molecules
EP1638510B1 (en) 2003-07-01 2015-09-02 Immunomedics, Inc. Multivalent carriers of bi-specific antibodies
JP4934426B2 (ja) 2003-08-18 2012-05-16 メディミューン，エルエルシー 抗体のヒト化
JP2007528723A (ja) 2003-08-22 2007-10-18 メディミューン，インコーポレーテッド 抗体のヒト化
CN100376599C (zh) 2004-04-01 2008-03-26 北京安波特基因工程技术有限公司 基因工程重组抗cea抗cd3抗cd28线性单链三特异抗体
JP2008500830A (ja) 2004-06-01 2008-01-17 ドマンティス リミテッド 増加した血清半減期を有する二重特異性融合抗体
WO2006020258A2 (en) 2004-07-17 2006-02-23 Imclone Systems Incorporated Novel tetravalent bispecific antibody
US20080069772A1 (en) 2004-08-26 2008-03-20 Eberhard-Karls-Universitaet Tuebingen Universitaetsklinikum Treatment of transformed or infected biological cells
EP1634603A1 (de) 2004-08-26 2006-03-15 Eberhard-Karls-Universität Tübingen Universitätsklinikum Behandlung von transformierten oder infizierten biologischen Zellen
FR2879605B1 (fr) 2004-12-16 2008-10-17 Centre Nat Rech Scient Cnrse Production de formats d'anticorps et applications immunologiques de ces formats
PT1699826E (pt) 2005-01-05 2009-06-17 F Star Biotech Forsch & Entw Domínios de imunoglobulina sintética com propriedades de ligação construídos em regiões da molécula diferentes das regiões determinantes de complementaridade
US7833979B2 (en) 2005-04-22 2010-11-16 Amgen Inc. Toxin peptide therapeutic agents
US20060252096A1 (en) 2005-04-26 2006-11-09 Glycofi, Inc. Single chain antibody with cleavable linker
RU2464276C2 (ru) 2005-05-18 2012-10-20 Аблинкс Н.В. Улучшенные нанотела против фактора некроза опухоли-альфа
KR101414438B1 (ko) 2005-05-20 2014-07-10 아블린쓰 엔.브이. 폰 빌레브란트 인자에 대한 단일 도메인 ｖｈｈ 항체
EP1726650A1 (en) 2005-05-27 2006-11-29 Universitätsklinikum Freiburg Monoclonal antibodies and single chain antibody fragments against cell-surface prostate specific membrane antigen
SG2014010029A (en) 2005-08-19 2014-08-28 Abbott Lab Dual variable domain immunoglobin and uses thereof
EP3178850B1 (en) 2005-10-11 2021-01-13 Amgen Research (Munich) GmbH Compositions comprising cross-species-specific antibodies and uses thereof
JP5102772B2 (ja) 2005-11-29 2012-12-19 ザ・ユニバーシティ・オブ・シドニー デミボディ：二量体化活性化治療剤
WO2007115230A2 (en) 2006-03-30 2007-10-11 University Of Medicine And Dentistry Of New Jersey A strategy for homo- or hetero-dimerization of various proteins in solutions and in cells
US20070269422A1 (en) 2006-05-17 2007-11-22 Ablynx N.V. Serum albumin binding proteins with long half-lives
EP2057191A1 (en) 2006-08-18 2009-05-13 Ablynx N.V. Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling
EP2069402A2 (en) 2006-09-08 2009-06-17 Ablynx N.V. Serum albumin binding proteins with long half-lives
US20100166734A1 (en) 2006-12-20 2010-07-01 Edward Dolk Oral delivery of polypeptides
AU2008234020B2 (en) 2007-04-03 2013-02-07 Amgen Research (Munich) Gmbh Cross-species-specific CD3-epsilon binding domain
WO2008142164A2 (en) 2007-05-24 2008-11-27 Ablynx N.V. Amino acid sequences directed against rank-l and polypeptides comprising the same for the treatment of bone diseases and disorders
EP2014680A1 (en) 2007-07-10 2009-01-14 Friedrich-Alexander-Universität Erlangen-Nürnberg Recombinant, single-chain, trivalent tri-specific or bi-specific antibody derivatives
US20090304719A1 (en) 2007-08-22 2009-12-10 Patrick Daugherty Activatable binding polypeptides and methods of identification and use thereof
CA2698419C (en) 2007-09-07 2019-11-12 Edward Dolk Binding molecules with multiple binding sites, compositions comprising the same and uses thereof
CN104004088B (zh) 2007-09-26 2017-11-07 Ucb医药有限公司 双特异性抗体融合物
CA2726652A1 (en) 2008-06-05 2009-12-10 Ablynx N.V. Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases
US20100122358A1 (en) 2008-06-06 2010-05-13 Crescendo Biologics Limited H-Chain-only antibodies
US8444976B2 (en) 2008-07-02 2013-05-21 Argen-X B.V. Antigen binding polypeptides
US20110177070A1 (en) 2008-07-02 2011-07-21 Emergent Product Development Seatlle, LLC TGF-Beta Antagonist Multi-Target Binding Proteins
HRP20160857T4 (hr) * 2008-10-01 2022-12-09 Amgen Research (Munich) Gmbh Bispecifična jednolančana protutijela, specifična za visokomolekulske ciljne antigene
AU2009299794B2 (en) 2008-10-01 2015-08-13 Amgen Research (Munich) Gmbh Cross-species-specific single domain bispecific single chain antibody
SG194398A1 (en) 2008-10-01 2013-11-29 Amgen Res Munich Gmbh Cross-species-specific psmaxcd3 bispecific single chain antibody
US9327022B2 (en) 2008-10-14 2016-05-03 National Research Council Of Canada BSA-specific antibodies
JP2012511033A (ja) 2008-12-08 2012-05-17 テゴファーム コーポレーション 多価化合物の可逆阻害用マスキングリガンド
JP5851842B2 (ja) 2009-01-12 2016-02-03 サイトムエックス セラピューティクス, インク.CytomX Therapeutics, Inc. 改変した抗体組成物、それを作製および使用する方法
EP2210902A1 (en) 2009-01-14 2010-07-28 TcL Pharma Recombinant monovalent antibodies
NZ594514A (en) 2009-03-05 2013-06-28 Abbott Lab Interleukin-17 BINDING PROTEINS
US20110195494A1 (en) 2009-10-02 2011-08-11 Boehringer Ingelheim International Gmbh Dll4-binging molecules
WO2011051327A2 (en) 2009-10-30 2011-05-05 Novartis Ag Small antibody-like single chain proteins
US10584181B2 (en) 2009-12-04 2020-03-10 Genentech, Inc. Methods of making and using multispecific antibody panels and antibody analog panels
EP2332994A1 (en) 2009-12-09 2011-06-15 Friedrich-Alexander-Universität Erlangen-Nürnberg Trispecific therapeutics against acute myeloid leukaemia
MX341796B (es) 2009-12-29 2016-09-02 Emergent Product Dev Seattle Proteinas de union heterodimericas y usos de las mismas.
GB2476681B (en) 2010-01-04 2012-04-04 Argen X Bv Humanized camelid VH, VK and VL immunoglobulin domains
EP4012714A1 (en) 2010-03-23 2022-06-15 Iogenetics, LLC. Bioinformatic processes for determination of peptide binding
WO2011117423A1 (en) 2010-03-26 2011-09-29 Ablynx N.V. Immunoglobulin single variable domains directed against cxcr7
US9556273B2 (en) 2010-03-29 2017-01-31 Vib Vzw Anti-macrophage mannose receptor single variable domains for targeting and in vivo imaging of tumor-associated macrophages
WO2012025525A1 (en) 2010-08-24 2012-03-01 Roche Glycart Ag Activatable bispecific antibodies
CA2807278A1 (en) 2010-08-24 2012-03-01 F. Hoffmann - La Roche Ag Bispecific antibodies comprising a disulfide stabilized - fv fragment
EP2621953B1 (en) 2010-09-30 2017-04-05 Ablynx N.V. Biological materials related to c-met
EP3974453A3 (en) 2010-11-16 2022-08-03 Amgen Inc. Agents and methods for treating diseases that correlate with bcma expression
JP6130350B2 (ja) 2011-03-30 2017-05-17 アブリンクス エン．ヴェー． ＴＮＦαに対する単一ドメイン抗体で免疫障害を処置する方法
TR201815488T4 (tr) 2011-04-08 2018-11-21 Health Anti-epidermal büyüme faktör reseptörü varyant III kimerik antijen reseptörleri ve kanser tedavisi için kullanımı.
WO2012158818A2 (en) 2011-05-16 2012-11-22 Fabion Pharmaceuticals, Inc. Multi-specific fab fusion proteins and methods of use
UA117901C2 (uk) 2011-07-06 2018-10-25 Ґенмаб Б.В. Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
WO2013036130A1 (en) 2011-09-09 2013-03-14 Universiteit Utrecht Holding B.V. Broadly neutralizing vhh against hiv-1
EP2758436B1 (en) * 2011-09-23 2019-06-12 Universität Stuttgart Serum half-life extension using immunoglobulin binding domains
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
NO2802607T3 (es) 2012-01-13 2018-03-03
WO2013110531A1 (en) 2012-01-23 2013-08-01 Ablynx Nv Sequences directed against hepatocyte growth factor (hgf) and polypeptides comprising the same for the treatment of cancers and/or tumors
AU2013203459B2 (en) 2012-02-24 2016-11-03 Abbvie Stemcentrx Llc DLL3 modulators and methods of use
GB201203442D0 (en) 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
WO2013128027A1 (en) 2012-03-01 2013-09-06 Amgen Research (Munich) Gmbh Long life polypeptide binding molecules
JP6283017B2 (ja) 2012-03-30 2018-02-21 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ プロテアーゼ制御抗体
IN2014MN02293A (es) 2012-04-20 2015-08-07 Emergent Product Dev Seattle
US9856314B2 (en) 2012-06-22 2018-01-02 Cytomx Therapeutics, Inc. Activatable antibodies having non-binding steric moieties and methods of using the same
WO2014004549A2 (en) 2012-06-27 2014-01-03 Amgen Inc. Anti-mesothelin binding proteins
CN112587671A (zh) 2012-07-18 2021-04-02 博笛生物科技有限公司 癌症的靶向免疫治疗
IN2015DN00138A (es) * 2012-08-31 2015-06-12 Argen X Bv
KR101963231B1 (ko) 2012-09-11 2019-03-28 삼성전자주식회사 이중특이 항체의 제작을 위한 단백질 복합체 및 이를 이용한 이중특이 항체 제조 방법
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
WO2014052064A1 (en) 2012-09-27 2014-04-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Mesothelin antibodies and methods for eliciting potent antitumor activity
JO3519B1 (ar) 2013-01-25 2020-07-05 Amgen Inc تركيبات أجسام مضادة لأجل cdh19 و cd3
AU2014225788B2 (en) 2013-03-05 2018-03-29 Baylor College Of Medicine Engager cells for immunotherapy
US10000546B2 (en) 2013-03-13 2018-06-19 Health Research, Inc. Compositions and method for use of recombinant T cell receptors for direct recognition of tumor antigen
US20140302037A1 (en) 2013-03-15 2014-10-09 Amgen Inc. BISPECIFIC-Fc MOLECULES
LT2970449T (lt) 2013-03-15 2019-11-25 Amgen Res Munich Gmbh Viengrandės surišančios molekulės, apimančios n galo abp
JP6404313B2 (ja) 2013-03-15 2018-10-10 アムジエン・インコーポレーテツド ヘテロ二量体性二重特異性抗体
PL3406633T3 (pl) 2013-07-25 2022-05-23 Cytomx Therapeutics Inc. Przeciwciała wieloswoiste, aktywowalne przeciwciała wieloswoiste i metody ich stosowania
WO2015048081A1 (en) 2013-09-24 2015-04-02 Andre Lieber Desmoglein 2 (dsg2) binding proteins and uses therefor
AU2014326674B2 (en) * 2013-09-26 2020-03-12 Ablynx Nv Bispecific nanobodies
RU2769133C2 (ru) 2013-12-30 2022-03-28 Эпимаб Биотерапьютикс Инк. Иммуноглобулин с тандемным расположением fab-фрагментов и его применение
UA117289C2 (uk) 2014-04-02 2018-07-10 Ф. Хоффманн-Ля Рош Аг Мультиспецифічне антитіло
WO2015184207A1 (en) 2014-05-29 2015-12-03 Macrogenics, Inc. Tri-specific binding molecules that specifically bind to multiple cancer antigens and methods of use thereof
GB201412659D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
CA2952540C (en) 2014-07-31 2022-06-21 Amgen Research (Munich) Gmbh Bispecific single chain antibody construct with enhanced tissue distribution
UY36245A (es) 2014-07-31 2016-01-29 Amgen Res Munich Gmbh Constructos de anticuerpos para cdh19 y cd3
JP6805130B2 (ja) 2014-09-05 2020-12-23 ヤンセン ファーマシューティカ エヌ．ベー． Ｃｄ１２３結合剤及びその使用
CN105471609B (zh) 2014-09-05 2019-04-05 华为技术有限公司 一种用于配置业务的方法和装置
US20170247476A1 (en) 2014-09-25 2017-08-31 Amgen Inc. Protease-activatable bispecific proteins
MX2017004603A (es) 2014-10-07 2017-06-30 Cellectis Metodo para modular actividad de celulas inmunes inducidas por car.
US10526417B2 (en) 2014-11-26 2020-01-07 Xencor, Inc. Heterodimeric antibodies that bind CD3 and CD38
EP3237449A2 (en) 2014-12-22 2017-11-01 Xencor, Inc. Trispecific antibodies
US10370435B2 (en) 2015-02-05 2019-08-06 Janssen Vaccines & Prevention B.V. Binding molecules directed against influenza hemagglutinin and uses thereof
US20180022819A1 (en) 2015-02-11 2018-01-25 Aptevo Research And Development Llc Compositions and methods for combination therapy with prostate-specific membrane antigen binding proteins
EP3286320A2 (en) 2015-04-22 2018-02-28 Agbiome, Inc. Insecticidal genes and methods of use
WO2016179003A1 (en) 2015-05-01 2016-11-10 Genentech, Inc. Masked anti-cd3 antibodies and methods of use
CN111234027A (zh) * 2015-05-21 2020-06-05 哈普恩治疗公司 三特异性结合蛋白质及使用方法
ES2881683T3 (es) 2015-05-21 2021-11-30 Full Spectrum Genetics Inc Procedimiento para mejorar las características de las proteínas
BR112017025929A2 (pt) 2015-06-03 2018-08-14 Agbiome Inc genes pesticidas e métodos de uso
CA2986604A1 (en) 2015-06-26 2016-12-29 University Of Southern California Masking chimeric antigen receptor t cells for tumor-specific activation
TWI796283B (zh) 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Ｍｓｌｎ及ｃｄ３抗體構築體
EP3331913A1 (en) 2015-08-07 2018-06-13 Novartis AG Treatment of cancer using chimeric cd3 receptor proteins
WO2017025698A1 (en) 2015-08-11 2017-02-16 Queen Mary University Of London Bispecific, cleavable antibodies
CN106519037B (zh) 2015-09-11 2019-07-23 科济生物医药（上海）有限公司 可活化的嵌合受体
CA3004299A1 (en) 2015-11-05 2017-05-11 City Of Hope Methods for preparing cells for adoptive t cell therapy
CA3003482A1 (en) 2015-11-19 2017-05-26 Revitope Limited Functional antibody fragment complementation for a two-components system for redirected killing of unwanted cells
US10093694B2 (en) 2016-02-03 2018-10-09 Guangzhou Kangrui Biological Pharmaceutical Technology Co, Ltd. Compounds for treating eye disorders or diseases
EP3426689A4 (en) 2016-03-08 2020-01-15 Maverick Therapeutics, Inc. INDUCTIBLE BINDING PROTEINS AND METHODS OF USE
CN109476756B (zh) 2016-03-15 2022-05-31 埃泰美德(香港)有限公司 一种多特异性Fab融合蛋白及其用途
EP3493844A4 (en) 2016-05-20 2021-03-24 Harpoon Therapeutics Inc. SINGLE DOMAIN SERIAL ALBUMIN BINDING PROTEIN
MX2018014227A (es) 2016-05-20 2019-08-22 Harpoon Therapeutics Inc Proteinas de union de cadena unica de fragmento variable cd3.
TW201815825A (zh) 2016-07-21 2018-05-01 財團法人生物技術開發中心 經修飾之抗原結合fab片段及包含其之抗原結合分子
US20190225702A1 (en) 2016-10-14 2019-07-25 Harpoon Therapeutics, Inc. Innate immune cell trispecific binding proteins and methods of use
CN110198955A (zh) 2016-11-23 2019-09-03 哈普恩治疗公司 前列腺特异性膜抗原结合蛋白质
MX2019006045A (es) 2016-11-23 2019-11-11 Harpoon Therapeutics Inc Proteinas triespecificas dirigidas a psma y metodos de uso.
WO2018136725A1 (en) 2017-01-19 2018-07-26 Harpoon Therapeutics, Inc. Innate immune cell inducible binding proteins and methods of use
WO2018160671A1 (en) 2017-02-28 2018-09-07 Harpoon Therapeutics, Inc. Targeted checkpoint inhibitors and methods of use
US11535668B2 (en) 2017-02-28 2022-12-27 Harpoon Therapeutics, Inc. Inducible monovalent antigen binding protein
EP3592775A1 (en) 2017-03-09 2020-01-15 CytomX Therapeutics, Inc. Cd147 antibodies, activatable cd147 antibodies, and methods of making and use thereof
WO2018204717A1 (en) 2017-05-03 2018-11-08 Harpoon Therapeutics, Inc. Compositions and methods for adoptive cell therapies
JP7209936B2 (ja) 2017-05-12 2023-01-23 ハープーン セラピューティクス，インク． Ｍｓｌｎ標的三重特異性タンパク質及びその使用方法
CN113896792A (zh) 2017-05-12 2022-01-07 哈普恩治疗公司 间皮素结合蛋白质
AU2018347582A1 (en) 2017-10-13 2020-05-07 Harpoon Therapeutics, Inc. Trispecific proteins and methods of use
KR20220111743A (ko) 2017-10-13 2022-08-09 하푼 테라퓨틱스, 인크. B 세포 성숙화 항원 결합 단백질
JP2021523192A (ja) 2018-05-14 2021-09-02 ハープーン セラピューティクス，インク． 免疫グロブリン分子の条件的活性化のための結合部分
WO2019222278A1 (en) 2018-05-14 2019-11-21 Harpoon Therapeutics, Inc. Dual binding moiety
US20210269530A1 (en) 2018-05-14 2021-09-02 Harpoon Therapeutics, Inc. Conditionally activated binding protein comprising a sterically occluded target binding domain
WO2020061482A1 (en) 2018-09-21 2020-03-26 Harpoon Therapeutics, Inc. Egfr binding proteins and methods of use
WO2020061526A1 (en) 2018-09-21 2020-03-26 Harpoon Therapeutics, Inc. Conditionally activated target-binding molecules
WO2020060593A1 (en) 2018-09-21 2020-03-26 Harpoon Therapeutics, Inc. Conditionally active receptors
US10815311B2 (en) 2018-09-25 2020-10-27 Harpoon Therapeutics, Inc. DLL3 binding proteins and methods of use
CN109593786A (zh) 2019-01-09 2019-04-09 上海怡豪生物科技有限公司 联合EpCAM和MSLN单链抗体的双靶点CAR载体及其构建方法和在乳腺癌应用

Also Published As

Publication number Publication date
IL266801A (en) 2019-07-31
CA3044729A1 (en) 2018-05-31
US20210095047A1 (en) 2021-04-01
BR112019010602A2 (pt) 2019-12-17
US20180162949A1 (en) 2018-06-14
JP2019535763A (ja) 2019-12-12
CN110198737A (zh) 2019-09-03
WO2018098356A1 (en) 2018-05-31
KR20190087539A (ko) 2019-07-24
AU2017363302A1 (en) 2019-06-27
EP3544629A4 (en) 2020-06-17
EP3544629A1 (en) 2019-10-02
JP7215997B2 (ja) 2023-01-31
US10844134B2 (en) 2020-11-24

Similar Documents

Publication Publication Date Title
MX2019006045A (es) Proteinas triespecificas dirigidas a psma y metodos de uso.
ZA202002094B (en) Trispecific proteins and methods of use
MX2017014908A (es) Proteinas de union triespecificas y metodos de uso.
MX2021003554A (es) Proteinas de union a dll3 y metodos de uso.
MX2018010824A (es) Proteinas de union inducibles y metodos de uso.
SA518400424B1 (ar) جزيئات الجسم المضاد لعلاج السرطان
PH12018502361A1 (en) Gdf15 fusion proteins and uses thereof
BR112019023856A2 (pt) proteínas triespecíficas que visam msln e métodos de utilização
MX2021014007A (es) Proteinas de union a epcam y metodos de uso.
AU2018236742B2 (en) Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
SA520411173B1 (ar) Pd-l1 عوامل ربط ترتبط بـ واستخدامها cd137
PH12019500709A1 (en) Anti-lag-3 antibodies and methods of use thereof
MX2024009690A (es) Anticuerpos anti-cd137 y metodos de uso de los mismos.
PH12020551907A1 (en) Antagonizing cd73 antibody
WO2019002444A9 (en) NEW T CELL RECEPTORS AND IMMUNOTHERAPY USING THE SAME
MX2019006043A (es) Proteína de unión de antígeno prostático específico de membrana.
SA522432139B1 (ar) بروتينات ربط متعددة الخصوصية لمعالجة السرطان
EP4406585A3 (en) Nucleic acid products and methods of administration thereof
PH12019500571A1 (en) Anti-pd-1 antibodies
MX2018015110A (es) Arn modificado que codifica polipeptidos de vegf-a. formulaciones y usos relacionados con los mismos.
PH12020550483A1 (en) Anti-apoc3 antibodies and methods of use thereof
MX2018010196A (es) Proteinas de fusion de enzimas lisosomales terapeuticas dirigidas, formulaciones asociadas y usos de las mismas.
WO2018129451A3 (en) Anti-fgfr antibodies and methods of use
EA201991181A1 (ru) Psma-нацеленные триспецифические белки и способы их применения
EA201992692A1 (ru) Нацеленные на msln триспецифические белки и способы применения